Joseph J. Eron, M.D., reviews highlights of ICAAC, including 48-week data on maraviroc, a head-to-head comparison of darunavir + ritonavir to lopinavir/ritonavir in treatment-naive patients, and the results of a study using interleukin-2 to delay HAART initiation.